A multicenter cohort study to investigate the factors associated with functional autonomy change in patients with cognitive complaint or neurocognitive disorders: the MEMORA study protocol

Virginie Dauphinot, Claire Moutet, Isabelle Rouch, Mathieu Verdurand, Christelle Mouchoux, Floriane Delphin-Combe, Sylvain Gaujard, Pierre Krolak-Salmon, MEMORA group, Pierre Krolak-Salmon, Virginie Dauphinot, Florian Delphin-Combe, Zaza Makaroff, Denis Federico, Marie-Hélène Coste, Isabelle Rouch, Jean-Michel Dorey, Alexis Lepetit, Keren Danaila, Julien Vernaudon, Anthony Bathsavanis, Alain Sarciron, Yves Guilhermet, Sylvain Gaujard, Pierre Gromaître, Claire Moutet, Mathieu Verdurand, Virginie Dauphinot, Claire Moutet, Isabelle Rouch, Mathieu Verdurand, Christelle Mouchoux, Floriane Delphin-Combe, Sylvain Gaujard, Pierre Krolak-Salmon, MEMORA group, Pierre Krolak-Salmon, Virginie Dauphinot, Florian Delphin-Combe, Zaza Makaroff, Denis Federico, Marie-Hélène Coste, Isabelle Rouch, Jean-Michel Dorey, Alexis Lepetit, Keren Danaila, Julien Vernaudon, Anthony Bathsavanis, Alain Sarciron, Yves Guilhermet, Sylvain Gaujard, Pierre Gromaître, Claire Moutet, Mathieu Verdurand

Abstract

Background: The identification of factors associated with functional impairment, in particular those which are potentially modifiable, may help to delay the advanced stages of functional dependence in patients with neurocognitive disorders such as Alzheimer's disease and related disorders. The objectives of the MEMORA cohort are to investigate the factors associated, first with functional autonomy change over time, and secondarily with the cognitive performance and behavioral disorders changes over time.

Methods: The MEMORA study is a multicenter prospective cohort study carried out throughout the patient's care pathway, in Memory centers of Lyon (France). The study will include 6780 patients at all stages of memory disorders in 6 years. The follow-up for each patient is planned for 3 years. The main outcome is the functional autonomy level change as assessed by the instrumental abilities of daily living (IADL) score. Patient characteristics include sociodemographic and clinical features, neuropsychological performance, pharmaceutical and non-pharmaceutical therapy.

Discussion: This study conducted in a context of routine care may help to identify the factors associated with functional impairment related to progressive neurocognitive disorders. Subsequently, interventions on potentially modifiable factors could be proposed to the patients to improve their management and delay functional dependence.

Trial registration: NCT02302482 , registered 27 November 2014.

Keywords: Activity of daily living; Longitudinal study; Memory; Neurocognitive disorders.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377:1019–1031. doi: 10.1016/S0140-6736(10)61349-9.
    1. Tschanz JT, Corcoran C, Schwartz S, et al. Progression of cognitive, functional and neuropsychiatric symptom domains in a population cohort with Alzheimer’s dementia the Cache County dementia progression study. Am J Geriatr Psychiatry. 2011;19:532–542. doi: 10.1097/JGP.0b013e3181faec23.
    1. Toot S, Swinson T, Devine M, Challis D, Orrel M. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr. 2017;29:195–208. doi: 10.1017/S1041610216001654.
    1. Lipnicki DM, Crawford J, Kochan NA, et al. Risk factors for mild cognitive impairment, dementia and mortality: the Sydney memory and ageing study. J Am Med Dir Assoc. 2017;18:388–95.
    1. Abellan van Kan G, Rolland Y, Nourhashémi F, Coley N, Andrieu S, Vellas B. Cardiovascular disease risk factors and progression of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009;27:240–246. doi: 10.1159/000203365.
    1. Musicco M, Palmer K, Salamone G, et al. Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. J Neurol. 2009;256:1288–1295. doi: 10.1007/s00415-009-5116-4.
    1. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6:551–559. doi: 10.1038/nrneurol.2010.130.
    1. Barocco F, Spallazzi M, Concari L, Gardini S, Pelosi A, Caffarra P. The progression of Alzheimer’s disease: are fast decliners really fast? A four-year follow-up. J Alzheimers Dis. 2017;57:775–786. doi: 10.3233/JAD-161264.
    1. Pérès K, Verret C, Alium A, Barberger-Gateau P. The disablement process: factors associated with progression to disability and recovery in French elderly people. Disabil Rehabil. 2005;27:263–276. doi: 10.1080/09638280400006515.
    1. Dharmasaroja PA, Lolekha P, Kulkantrakorn K, Charernboon T, Watcharakorn A, Piyabhan P. Natural course and predictors of severe disability and death in Thai patients with dementia. J Clin Neurosci. 2017;46:37–40. doi: 10.1016/j.jocn.2017.08.040.
    1. Lechowski L, De Stampa M, Tortrat D, et al. Predictive factors of rate of loss of autonomy in Alzheimer’s disease patients. A prospective study of the cohort. J Nutr Health Aging. 2005;9:100–104.
    1. Palmer K, Lupo F, Perri R, et al. Predicting disease progression in Alzheimer's disease: the role of neuropsychiatric syndromes on functional and cognitive decline. J Alzheimers Dis. 2011;24:35–45. doi: 10.3233/JAD-2010-101836.
    1. McLaren AN, Lamantia MA, Callahan CM. Systematic review of non-pharmacologic interventions to delay functional decline in community-dwelling patients with dementia. Aging Ment Health. 2013;17(6):655–666. doi: 10.1080/13607863.2013.781121.
    1. Rosenberg PB, Mielke MM, Tschanz J, et al. Effects of cardiovascular medications on rate of funtional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:883–892. doi: 10.1097/JGP.0b013e318181276a.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC; 2013. .
    1. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:844–852. doi: 10.1016/j.jalz.2014.01.001.
    1. Lawton M, Brody E. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–186. doi: 10.1093/geront/9.3_Part_1.179.
    1. de Rotrou J, Wu YH, Hugonot-Diener L, et al. DAD-6: a 6-item version of the disability assessment for dementia scale which may differenciate Alzheimer's disease and mild cognitive impairment from controls. Dement Geriatr Cogn Disord. 2012;33:210–218. doi: 10.1159/000338232.
    1. Folstein M, Folstein S. Mini-mental state: a practical method for grading the cognitive Stade of patients for the clinician. J Psychiatr Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Mckeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005;4:735–742. doi: 10.1016/S1474-4422(05)70219-2.
    1. Revel V, Haritchabalet I, Kervinio C, et al. Construction d'une échelle simplifiée pour la détection en médecine générale du fardeau de l'aidant d'une personne âgée dépendante. L'année gérontologique. 2002;16:131–137.
    1. Ferro MA. Missing data in longitudinal studies: cross-sectional multiple imputation provides similar estimates to full-information maximum likelihood. Ann Epidemiol. 2014;24:75–77. doi: 10.1016/j.annepidem.2013.10.007.
    1. Twisk J, de Boer M, de Vente W, Heymans M. Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis. J Clin Epidemiol. 2013;66:1022–1028. doi: 10.1016/j.jclinepi.2013.03.017.
    1. Locascio JJ, Atri A. An overview of longitudinal data analysis methods for neurological research. Dement Geriatr Cogn Disord. 2011;1:330–357. doi: 10.1159/000330228.
    1. Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol. 2012;65:1171–1180. doi: 10.1016/j.jclinepi.2012.04.008.
    1. Liu S, Rovine MJ, Molenaar PC. Selecting a linear mixed model for longitudinal data: repeated measures analysis of variance, covariance pattern model, and growth curve approaches. Psychol Methods. 2012;17:15–30. doi: 10.1037/a0026971.
    1. Maisonneuve H, Babany G. Données de vie réelle et recherche clinique: le complément des données des essais randomisés? Presse Med. 2015;44:586–589. doi: 10.1016/j.lpm.2015.02.005.
    1. Callahan CM, Boustani MA, Schmid AA, et al. Targeting functional decline in Alzheimer disease. Ann Intern Med. 2017;166:164–171. doi: 10.7326/M16-0830.
    1. Vellas B, Andrieu S, Sampaio C, Caley N, Wilcock G. Endpoints for trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol. 2008;7:436–450. doi: 10.1016/S1474-4422(08)70087-5.
    1. Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011;7:318–327. doi: 10.1016/j.jalz.2010.09.001.
    1. Hill J, Fillit H, Thomas S, Chang S. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer’s disease and other dementias. Pharmacoeconomics. 2006;24:265–280. doi: 10.2165/00019053-200624030-00006.
    1. Joling KJ, Schöpe J, van Hout HP, van Marwijk HW, van der Horst HE, Bosmans JE. Predictors of societal costs in dementia patients and their informal caregivers: a two-year prospective cohort stud. Am J Geriatr Psychiatry. 2015;23:1193–1203. doi: 10.1016/j.jagp.2015.06.008.
    1. Garrison LJ, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10:326–335. doi: 10.1111/j.1524-4733.2007.00186.x.
    1. Weuve J, Proust-Lima C, Power MC, et al. Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. Alzheimers Dement. 2015;11:1098–1109. doi: 10.1016/j.jalz.2015.06.1885.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다